Unveiling 4 Analyst Insights On Genelux

Genelux (NASDAQ:GNLX) underwent analysis by 4 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.Summarizing their recent assessments, the table below illustrates

BenzingaMay 31 12:01 ET

Genelux Is Maintained at Speculative Buy by Benchmark

Genelux Is Maintained at Speculative Buy by Benchmark

Dow JonesMay 31 11:22 ET

Genelux Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/31/2024 832.84% Benchmark $30 → $25 Maintains Speculative Buy 05/13/2024 1094.03% HC Wainwright & Co. →

BenzingaMay 31 11:11 ET

Express News | Genelux Corp : Benchmark Cuts Target Price to $25 From $30

ReutersMay 31 06:22 ET

12 Health Care Stocks Moving In Monday's Pre-Market Session

GainersCue Health (NASDAQ:HLTH) stock moved upwards by 32.4% to $0.12 during Monday's pre-market session. The market value of their outstanding shares is at $19.8 million. SCWorx (NASDAQ:WORX) shares

BenzingaMay 27 08:05 ET

Top Midday Decliners

Verastem Oncology (VSTM) reported a phase 1/2 clinical trial evaluating avutometinib and defactinib in combination with gemcitabine and nab-paclitaxel in 41 patients with metastatic pancreatic cancer

MT NewswiresMay 24 14:20 ET